Skip to main content

BioNexus Gene Lab Corp

corporate_fare Company Profile

BioNexus Gene Lab Corp

BGLC·NASDAQ·Industrial Applications And Services·CIK 0001737523

BioNexus Gene Lab Corp. is a Wyoming corporation operating through two main subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. and MRNA Scientific Sdn. Bhd. Chemrex distributes chemical raw materials primarily for industrial applications across Southeast Asia, serving the industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in countries including Malaysia, Indonesia, and Vietnam. MRNA Scientific develops and provides blood-based genomic screening services for early disease risk assessment and health management. In November 2025, the company expanded its focus in molecular diagnostics and oncology-related screening technologies by entering into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte. Ltd. and related parties. Concurrently, it secured an exclusive, perpetual license for the VitaGuard™ Minimal Residual Disease (MRD) platform in the ASEAN region. The company's principal executive office is located in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp (NASDAQ:BGLC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 10 items for BGLC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for BGLC spans 10-Q, 8-K, SCHEDULE 13D, 10-K.

Recent high-impact activity:

  • BioNexus Q3: Revenue Down 97.9%, Going Concern Doubt Reiterated, 560K Shares Issued for RYET Deal
  • BioNexus Grants Exclusive CogniAI Healthcare Licence and Issues 16% of Shares to RYET
  • CEO Su-Leng Tan Lee Receives 338,709 Fully Vested Shares, Boosting Stake to 11.5%
  • BioNexus Issues $800K in Stock Awards, Reappoints CEO, and Reiterates Going Concern Doubt
  • BioNexus Gene Lab Corp's Q1 Revenue Crashes 99% to $22.84K, Deepening Going Concern Worries

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$7.42M
Net Income
-$2.98M
Op. Cash Flow
-$1.84M
Free Cash Flow
-$1.88M
Gross Profit
$1.09M
Operating Income
-$2.97M
Cash & Equivalents
$2.49M
Debt / Equity
0.00×
Net Margin
-40.2%
Shares Outstanding
2.42M sh
Source: 10-K · filed 2026-04-14 · accession 0001477932-26-002218

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 3,180 shares in BGLC as of the October 30, 2026 settlement, a 64.9% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 10.7% of BGLC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,180 shares as of October 30, 2026
Change vs prior period▼ 64.9%
Days to cover1.00 at avg daily volume of 3,299
Daily short volume (FINRA facilities)10.7% of 2,364 shares on November 20, 2026
5-day average short volume18.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with B →
$0.68
52-week range · as of 2026-11-19 $0.621 – $4.97
Market cap
$2.38M
Volume
3.1K (0.5× avg)
3-mo avg 6.5K
Live data · 2026-11-22 03:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BGLC - Latest Insights

BGLC
Nov 19, 2026, 5:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.680
Real-time Price: $0.680 info
Change: $0 (0%) info
Market Cap: $2.376M info
BGLC
Oct 07, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.27
Real-time Price: $0.680 info
Change: -$0.590 (-46%) info
Market Cap: $2.376M info
BGLC
Aug 14, 2026, 5:29 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $1.57
Real-time Price: $0.680 info
Change: -$0.890 (-57%) info
Market Cap: $2.376M info
BGLC
Aug 14, 2026, 5:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.57
Real-time Price: $0.680 info
Change: -$0.890 (-57%) info
Market Cap: $2.376M info
BGLC
May 15, 2026, 5:21 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.02
Real-time Price: $0.680 info
Change: -$1.34 (-66%) info
Market Cap: $2.376M info
BGLC
May 15, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.02
Real-time Price: $0.680 info
Change: -$1.34 (-66%) info
Market Cap: $2.376M info
BGLC
Apr 14, 2026, 5:20 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.17
Real-time Price: $0.680 info
Change: -$1.49 (-69%) info
Market Cap: $2.376M info
BGLC
Mar 17, 2026, 2:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.54
Real-time Price: $0.680 info
Change: -$1.86 (-73%) info
Market Cap: $2.376M info
BGLC
Feb 23, 2026, 8:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.43
Real-time Price: $0.680 info
Change: -$1.75 (-72%) info
Market Cap: $2.376M info
BGLC
Feb 03, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.65
Real-time Price: $0.680 info
Change: -$1.97 (-74%) info
Market Cap: $2.376M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets